Exagen Appoints Michael Mahler, PhD, as Chief Scientific Officer to Boost Autoimmune Diagnostics Leadership

Exagen Inc., a pioneer in autoimmune disease diagnostics, has appointed Dr. Michael Mahler as Chief Scientific Officer. With a robust background in immunology, Dr. Mahler is expected to drive the strategic initiatives at Exagen, aiming to enhance diagnostics for autoimmune diseases. Having held prominent roles in various diagnostic firms, Dr. Mahler's past work has significantly contributed to the discovery of new autoantigens and advanced diagnostic solutions, amassing over 300 peer-reviewed publications and numerous patents. Exagen's President and CEO, John Aballi, expressed enthusiasm over Dr. Mahler's appointment, anticipating his role to be pivotal in advancing the company's diagnostic capabilities. Dr. Mahler himself is eager to integrate his 20 years of experience with Exagen's patient-focused approach, working on innovative projects to revolutionize autoimmune disease management. Exagen's flagship product, AVISE CTD, offers more precise diagnosis for complex autoimmune conditions like lupus and rheumatoid arthritis, while the company’s focus remains on research, education, and patient-centered care. Yet, Exagen cautions of inherent risks, including issues related to reimbursement decisions, regulatory delays, and market acceptance, stressing the uncertainty of achieving forward-looking statements.